Navigation Links
Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act
Date:12/9/2013

SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a pharmaceutical company focused on commercial development of novel drug formulations and drug delivery technologies announced their intention today to pursue a compounding pharmacy strategy in 2014 and beyond.

The recently passed Drug Quality and Security Act allows large drug-compounding facilities, which mix ingredients to make a custom blend of medicine, to register as "outsourcing facilities." Imprimis continues to track recent guidance from the FDA on the newly passed law and expects to participate in the discussion related to final rules for the implementation of the law and hopes to eventually establish and voluntarily register its outsourcing facilities and be subject to these requirements and regular FDA inspection.  

"We believe that bipartisan passage of this law sends a clear signal that our leaders in Washington recognize the broad benefits of compounding pharmacies and the important role they play in the evolving healthcare delivery landscape and we applaud their creation of a regulatory framework to oversee the compounding industry, which we believe is favorable to our business strategy," said Mark L. Baum, Chief Executive Officer of Imprimis.

"Establishing centers of pharmacy excellence that use the highest standards to make and then efficiently distribute our growing portfolio of proprietary compounded drug formulations will advance Imprimis' business strategy of taking small ideas from the clinical interaction between pharmacists, physicians and their patients and turning them into big ideas for physicians across America to prescribe as a compounded drug for their patients.  We believe that this idea in practice will reduce healthcare costs and provide American
'/>"/>

SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek as Vice-President of Commercialization for its Ophthalmology Division
2. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
3. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
4. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
5. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
6. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
7. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
8. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
9. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
10. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
11. Imprimis Announces Key Leadership Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... TUCSON, Ariz. , July 10, 2014   ... Roche  Group, today announced it has entered into an ... , which operates as EMD Serono in ... , to collaborate with Merck KGaA,s biopharmaceutical division ... (CDx) for an undisclosed target using Ventana,s proprietary diagnostic ...
(Date:7/10/2014)... 10, 2014 CVS Caremark Corporation (NYSE: ... approved a quarterly dividend of $0.275 (27.5 cents) per share ... August 1, 2014, to holders of record on July 21, ... Caremark is dedicated to helping people on their path to ... the United States . Through the company,s more ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... , ALLEGAN, Mich. , Jan. 27 ... Directors declared a quarterly dividend of $0.0625 per ... of record on February 26, 2010 . , Perrigo ... and distributes over-the-counter (OTC) and generic prescription pharmaceuticals, nutritional products, ...
... , NEW YORK , Jan. ... Investments, Inc. (NYSE Amex: MGT ), and an industry ... analysis software which assists radiologists in the early detection of ... received a further request for Additional Information (AI) letter from ...
Cached Medicine Technology:Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 2Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 3
(Date:7/12/2014)... Demand Response Management Systems is a crucial peak ... imbalance between energy supply and demand. With the help ... (due to increasing pressure on the grid) and replaced ... residential appliances and thermostats for load reduction. , ... and with government mandates and benefits for energy efficiency ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... (HealthDay News) -- Burn injuries increase in the summer as ... burn experts. Among those most vulnerable to these seasonal fire ... and often get burned by putting their hands on the ... the burn unit at Loyola University Medical Center in Maywood, ... adage of ,When you play with fire, you get burned, ...
(Date:7/12/2014)... July 12, 2014 “After my mom’s stroke, she ... a stroke and loss the use of his left side. Eating ... a way to help people like them enjoy eating again,” said ... prototype for the PATRICIA CAROL HALL PLATE (P C H PLATE). ... a more ergonomic way to eat for individuals who suffer from ...
(Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... clinical trial of the experimental drug dimebon (latrepirdine) in people ... cognition. That is the conclusion of a study published ... "This is the first clinical trial that has focused ... disease," said University of Rochester Medical Center neurologist Karl Kieburtz, ...
... with use, but other factors may contribute, experts say , ... treat glaucoma appear to outlive those who don,t treat the ... reduced risk for premature death stems from the glaucoma drugs ... access to health care remains unclear. , Use of glaucoma ...
... residue may give rise to new pollutants indoors, chemists ... smoke residue found on indoor surfaces -- so-called "third-hand ... new, potentially cancer-causing substances, research suggests. , Details about ... what health concerns it might create remain unclear, however, ...
... BOSTON , Feb. 8 The National Patient ... on March 7, 2010 , in a concerted effort ... of health care, and strengthen alliances between patients, families and ... During the week, participating hospitals and healthcare systems will plan ...
... , Feb. 8 Independence Blue Cross (IBC) today ... newly created role of senior vice president of marketing services. He ... executive, Linda M. Taylor . , In this new ... care consumers better manage their care and will also head product ...
... , Feb. 8 SpectraCell Laboratories announced that ... D.C. to its scientific staff as Director of Clinical Nutrition ... national basis and consult with clients on the implementation of ... is a long-time client of SpectraCell, using their micronutrient testing ...
Cached Medicine News:Health News:Drug shows promise for Huntington's disease 2Health News:Glaucoma Drugs May Play Role in Longer Life 2Health News:Glaucoma Drugs May Play Role in Longer Life 3Health News:'Third-Hand Smoke' Could Be Troublesome, Too 2Health News:'Third-Hand Smoke' Could Be Troublesome, Too 3Health News:National Patient Safety Foundation Leads Nationwide Effort to Promote Patient Safety 2Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 2Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 3Health News:Dr. Ron Grabowski Named Director of Clinical Nutrition and Education for SpectraCell Laboratories 2Health News:Dr. Ron Grabowski Named Director of Clinical Nutrition and Education for SpectraCell Laboratories 3
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
The D-Stat Radial hemostat band utilizes a compression band together with the active haemostatic material of the D-Stat to control surface bleeding....
Medicine Products: